Grant: Operating Grant: Priority Announcement - Transfusion Science
Centre hospitalier de l'Université de Montréal (CHUM)
$0.00
Myocardial Ischemia and Transfusion. The MINT Rollover Trial
EF 2014-15
Résumé
Heart attacks are conditions where blood flow to the heart muscle is dangerously low - eventually causing heart muscle to die. Drugs improving the blood flow, and procedures such angioplasty, are the mainstay of therapies. They will only work if there is enough oxygen transported in blood. In fact, the heart may be deprived of oxygen not only because of the heart attack itself but also because of low blood counts (or anemia). Anemia, or low blood counts, may be caused by bleeding or by conditions such as cancer, kidney failure, chronic infections or conditions such as severe arthritis. A transfusion increases the delivery of oxygen to the heart muscle. However, we do not know at what level of anemia to initiate blood transfusion to prevent permanent heart damage. Indeed, having low blood counts may be harmful but blood transfusions also carries important risks including extra fluid in the lungs and heart inability to pump effectively.
In previous studies, we demonstrated that giving less blood is safer in most patients. But, there is little evidence in patients with heart attack. This first pilot trial aims to make sure that a large study that will answer the question is doable. The large trial aims to determine when and how much blood to give to minimize damage. In both studies, we will divide patients who have a heart attack into two groups in the hopes of preventing patients from dying. One group will receive more blood and the other group less blood. In the pilot trial, we will evaluate if we can recruit patients with heart attack in a timely fashion. This trial, spanning over 12 months. If patient recruitment goes well, we will move ahead with the second phase of the project involving over 3500 patients. We plan to record the numbers of patients who die or have another heart attack as well as if doctors follow treatment plans. This 5-year large scale project will provide a definitive answer to the amount and optimal timing of blood transfusion.
Programme
Operating Grant: Priority Announcement - Transfusion Science
Emplacement
Quebec, Canada
Type de bénéficiaire
Not-for-profit organization or charity
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
329783
Name
Hebert Paul C
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Blood Services (Ottawa)
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials 2
Projecttitle
Myocardial Ischemia and Transfusion. The MINT Rollover Trial
Programtype2
Operating Grants
Orgnameinp2
Centre hospitalier de l'Université de Montréal (CHUM)
Cihramount2
$0
Cihrequipment2
$0
Programname2
Operating Grant: Priority Announcement - Transfusion Science
Keyworddelim
Blood Transfusions; Cardiology; Myocardial Ischemia; Randomized Controlled Trial
Abstract
Heart attacks are conditions where blood flow to the heart muscle is dangerously low - eventually causing heart muscle to die. Drugs improving the blood flow, and procedures such angioplasty, are the mainstay of therapies. They will only work if there is enough oxygen transported in blood. In fact, the heart may be deprived of oxygen not only because of the heart attack itself but also because of low blood counts (or anemia). Anemia, or low blood counts, may be caused by bleeding or by conditions such as cancer, kidney failure, chronic infections or conditions such as severe arthritis. A transfusion increases the delivery of oxygen to the heart muscle. However, we do not know at what level of anemia to initiate blood transfusion to prevent permanent heart damage. Indeed, having low blood counts may be harmful but blood transfusions also carries important risks including extra fluid in the lungs and heart inability to pump effectively.
In previous studies, we demonstrated that giving less blood is safer in most patients. But, there is little evidence in patients with heart attack. This first pilot trial aims to make sure that a large study that will answer the question is doable. The large trial aims to determine when and how much blood to give to minimize damage. In both studies, we will divide patients who have a heart attack into two groups in the hopes of preventing patients from dying. One group will receive more blood and the other group less blood. In the pilot trial, we will evaluate if we can recruit patients with heart attack in a timely fashion. This trial, spanning over 12 months. If patient recruitment goes well, we will move ahead with the second phase of the project involving over 3500 patients. We plan to record the numbers of patients who die or have another heart attack as well as if doctors follow treatment plans. This 5-year large scale project will provide a definitive answer to the amount and optimal timing of blood transfusion.
Competitiondate
201503
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Hebert, Paul C; Carson, Jeffrey L
Approvedterm
3 ans 0 mois